

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

October 31, 2022

To: Shareholders

Company Name: Renascience Inc  
Name of Representative: Koji Naito, President & CEO  
(Code: 4889 TSE Growth)  
Inquiries: Hiroyasu Ishimaru, Corporate Officer in charge of  
Administration and Corporate Planning

### **Announcement of Collaboration Agreement with Hiroshima University**

The Company hereby announces that the Company has resolved to enter into collaboration with Hiroshima University to investigate the efficacy and safety of the inhibitor for plasminogen activator inhibitor-1 (PAI-1) in combination with anticancer agents in the treatment of non-small cell lung cancer.

Although this matter does not meet the category of timely disclosure as stipulated by the rules of the Tokyo Stock Exchange, the Company considers the information is of value to the Shareholders, and therefore discloses this information voluntarily.

#### 1. Background and outline of the collaboration agreement

The Company is currently conducting a phase II investigator-initiated clinical trial for malignant melanoma based on the immune checkpoint inhibition by the PAI-1 inhibitor (RS5614). To further expand the indication of the drug in the field of oncology, the Company will initiate the collaboration with Hiroshima University (Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences) on non-clinical and clinical studies for non-small cell lung cancer. Specifically, we plan to conduct both a non-clinical study and a phase II investigator-initiated clinical study to explore the efficacy and safety of RS5614 in non-small cell lung cancer, in combination of the Company's RS5614 (PAI-1 inhibitor) with nivolumab and other anticancer agents.

#### 2. Outline of the collaboration partners

(1) Name	Hiroshima University
(2) Location	1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima
(3) Title and name of the representative	President Mitsuo Ochi
(4) Capital	147.2 billion yen
(5) Date of establishment	Establishment of Hiroshima University as the National University Corporation as of April 2004 (Hiroshima University was established in May 1949)
(6) Relationship of the Company with Hiroshima University	There are no applicable matters regarding capital relationship, personal relationship, business relationship, or related party relationship.

3. Outlook for the future

This matter will have no impact on the earnings forecast for the fiscal year ending March 31, 2023.

End